61241-07-4

Usage

Uses

Used in Pharmaceutical Industry:
4-Nitro-1H-pyrazole-3-carbonitrile is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structural properties and functional groups enable the development of new drugs with potential therapeutic applications.
Used in Organic Chemistry Research:
4-Nitro-1H-pyrazole-3-carbonitrile is used as a building block in the synthesis of heterocyclic compounds. Its diverse reactivity and functional groups make it a valuable tool for researchers in the field of organic chemistry, allowing for the exploration of new chemical compounds and their potential applications.
Used in Chemical Synthesis:
4-Nitro-1H-pyrazole-3-carbonitrile is used as a key component in the synthesis of various chemical compounds. Its presence in the molecular structure allows for the creation of new compounds with unique properties and potential uses in various industries.

InChI:InChI=1/C4H2N4O2/c5-1-3-4(8(9)10)2-6-7-3/h2H,(H,6,7)

Upstream product

• 65190-36-5 4-nitro-1H-pyrazole-5-carboxamide 
• 65190-36-5 4-nitro-1H-pyrazole-3-carboxamide 

Downstream Products

• 13877-56-0 7-aminopyrazolo<4,3-d>pyrimidine 
• 1094739-82-8 1-(2-bromo-3,4,5-trimethoxybenzyl)-4-nitro-1H-pyrazole-3-carbonitrile 
• 151599-40-5 1-methyl-4-nitro-1H-pyrazole-3-carbonitrile 
• 1426541-58-3 4-nitro-1-phenyl-1H-pyrazole-3-carbonitrile 
• 68703-67-3 4-amino-1H-pyrazole-5-carbonitrile 
• 68703-67-3 4-amino-1H-pyrazole-3-carbonitrile 

Relevant academic research and scientific papers

Design, synthesis, and cytotoxic activity of novel 2H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidine derivatives

In this study, a series of novel 2H-imidazo [1, 2-c] pyrazolo [3, 4-e] pyrimidine derivatives were designed, synthesized, and evaluated for their cytotoxic activities. The in vitro cell growth inhibition assay of the target compounds indicated their selectivity in inhibiting the proliferation of blood tumor cells (K562, U937) and solid tumor cells (HCT116, HT-29). Compound 9b exhibited the highest antiproliferative activities against K562 (IC50 = 5.597 μM) and U937 (IC50 = 3.512 μM). Based on the flow cytometry assays, compound 9b caused obvious induction of cell apoptosis and cell arrest at the S phase. Furthermore, western blot analysis revealed that compound 9b upregulated the expression of Bax, downregulated the levels of Bcl-2, and further activated caspase-3 in K562 cells. Therefore, compound 9b may be a potential anticancer agent that deserves further investigation.

Pyrazole-pyrimido imidazole compound as well as preparation method and application thereof

The invention relates to a pyrazole-pyrimido imidazole compound as well as a preparation method and application thereof, and belongs to the field of medicinal chemistry and pharmacotherapeutics. The invention provides application of the compound shown in the formula I or the pharmaceutically acceptable salt thereof in preparation of drugs for treating tumor-related diseases.

ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF

An ALK kinase inhibitor compound as represented by Formula I, pharmaceutical composition containing the compound, and preparation method and use thereof in the preparation of drugs serving as an ALK inhibitor for treating cancer.

Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors

A new series of 7-aminopyrazolo[4,3-d]pyrimidine derivatives (1-31) were synthesized to evaluate some structural modifications at the 2- and 5-positions aimed at shifting affinity towards the human (h) A2A adenosine receptor (AR) or both hA2A and hA1 ARs. The most active compounds were those featured by a 2-furyl or 5-methylfuran-2-yl moiety at position 5, combined with a benzyl or a substituted-benzyl group at position 2. Several of these derivatives (22-31) displayed nanomolar affinity for the hA2A AR (Ki = 3.62-57 nM) and slightly lower for the hA1 ARs, thus showing different degrees (3-22 fold) of hA2A versus hA1 selectivity. In particular, the 2-(2-methoxybenzyl)-5-(5-methylfuran-2-yl) derivative 25 possessed the highest hA2A and hA1 AR affinities (Ki = 3.62 nM and 18 nM, respectively) and behaved as potent antagonist at both these receptors (cAMP assays). Its 2-(2-hydroxybenzyl) analog 26 also showed a high affinity for the hA2A AR (Ki = 5.26 nM) and was 22-fold selective versus the hA1 subtype. Molecular docking investigations performed at the hA2A AR crystal structure and at a homology model of the hA1 AR allowed us to represent the hypothetical binding mode of our derivatives and to rationalize the observed SARs.

Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors

Anaplastic lymphoma kinase (ALK) is a highly attractive therapeutic target for the treatment of some non-small cell lung cancer patients. This Letter describes the further SAR exploration on the novel 3-sulfonylpyrazol-4-amino pyrimidine scaffold. This work identified a compound 53 with very good in vitro/in vivo efficacies, good DMPK properties together with better hERG tolerability and it is currently being profiled for the evaluation as a potential pre-clinical candidate.

Practical synthesis of novel purine analogues as Hsp90 inhibitors

The development of a straightforward synthesis of 4-amino-6-benzyl-6H-pyrrolo[3,4-d]pyrimidine and 7-amino-2-benzyl-2H-pyrazolo[4,3-d]pyrimidine derivatives allowed for the preparation of a small family of potential Hsp90 inhibitors. Some of the newly synthesized compounds showed Hsp90 inhibitory activity in preliminary biological assays.

Kinase inhibitors

The present application is directed to pyrazolopyrirnidine and furopyrimidine analogs of the formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.